These results suggest that RNF25 confers gefitinib resistance to EGFR-mutant lung cancer cells by mediating gefitinib-dependent induction of NF-κB signaling, while its loss sensitizes the gefitinib-resistant cells to the drug by suppressing the induction of NF-κB signaling. The gene discussed is EGFR; the disease is lung carcinoma.